Basic Information
| LncRNA/CircRNA Name | MALAT1 |
| Synonyms | MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853 |
| Region | GRCh38_11:65497688-65506516 |
| Ensemble | ENSG00000251562 |
| Refseq | NR_002819 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay etc. |
| Sample | OS tissues, cell lines (MG-63, SAOS-2, U2OS, SW1353, hFOB) |
| Expression Pattern | up-regulated |
| Function Description | MALAT1 was significantly increased in osteosarcoma specimens and cell lines. serum lncRNA MALAT1 expression has considerable diagnostic and prognostic significance in discriminating osteosarcoma patients and non-tumor patients. MALAT1 may serve as a promising prognostic and therapeutic target for osteosarcoma patients. MALAT1 overexpression promoted cell metastasis and decreased E-cadherin level, however, this effect was partially reversed by EZH2 knockdown. MALAT1 is a potential diagnostic and prognostic factor in osteosarcoma and further demonstrates how MALAT1 confers an oncogenic function. |
| Pubmed ID | 28388584 |
| Year | 2017 |
| Title | MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2. |
External Links
| Links for MALAT1 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |